176548-70-2

Basic information

• Product Name: 3-Bromo-5-fluorobenzoic acid
• Synonyms: 3-Bromo-5-fluorobenzoic acid 98%;5-fluoro-3-bromobenzoic acid;3-FLUORO-5-BROMOBENZOIC ACID 98%;3-BroMo-5-fluorobenzoic Acid, 97+%;3 - broMine - 5 - fluoro benzoic acid;5-BROMO-3-FLUOROBENZOIC ACID;3-FLUORO-5-BROMOBENZOIC ACID;3-BROMO-5-FLUOROBENZOIC ACID
• CAS NO: 176548-70-2
• Molecular Formula: C₇H₄BrFO₂
• Molecular Weight: 219.01
• EINECS: 630-193-2
• Product Categories: Fluorin-contained Benzoic acid series;blocks;Bromides;Carboxes;FluoroCompounds;Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Benzoic acid;Acids & Esters;Bromine Compounds;Fluorine Compounds;Benzoic acid series;intermediate
• Mol File: 176548-70-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 140 °C
• Boiling Point: 303.3 °C at 760 mmHg
• Flash Point: 137.3 °C
• Appearance: white solid
• Density: 1.789 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.524
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.47±0.10(Predicted)
• Water Solubility: Insoluble in water.
• CAS DataBase Reference: 3-Bromo-5-fluorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-fluorobenzoic acid(176548-70-2)
• EPA Substance Registry System: 3-Bromo-5-fluorobenzoic acid(176548-70-2)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-36-22
• Safety Statements: 26-36/37/39-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 176548-70-2(Hazardous Substances Data)

Usage

Chemical Properties

light yellow powder

Uses

3-Bromo-5-fluorobenzoic acid is an important raw material and intermediate used in organic synthesis, pharmaceuticals agrochemicals and dyestuff fields.

InChI:InChI=1/C8H7FO3/c1-12-7-3-5(8(10)11)2-6(9)4-7/h2-4H,1H3,(H,10,11)

Upstream product

• 124-38-9 carbon dioxide 
• 1435-51-4 1,3-dibromo-5-fluorobenzene 
• 179898-34-1 3-bromo-5-fluorobenzonitrile 
• 1073-06-9 3-fluorobromobenzene 
• 872545-52-3 (2-bromo-6-fluorophenyl)triethylsilane 

Downstream Products

• 216755-56-5 5-fluoro-3-hydroxymethylbromobenzene 
• 453565-93-0 3-fluoro-5-pyridin-3-yl-benzoic acid 
• 453566-50-2 3-(5-fluoro-pyridin-2-yl)-5-(3-fluoro-5-bromophenyl)-1,2,4-oxadiazole 
• 453566-48-8 3-(2-Pyridyl)-5-(3-fluoro-5-bromophenyl)-1,2,4-oxadiazole 
• 334792-52-8 methyl 3-bromo-5-fluoro-benzoate 
• 1403612-33-8 methyl 3-cyano-5-fluoro-4-iodobenzoate 
• 1403612-35-0 N'-[(3-cyano-5-fluoro-4-iodobenzoyl)oxy]-5-fluoropyridine-2-carboximidamide 
• 1403612-36-1 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]-2-iodobenzonitrile 
• 886732-29-2 methyl 3-cyano-5-fluorobenzoate 
• 1403612-34-9 3-cyano-5-fluoro-4-iodobenzoic acid 
• 1609677-89-5 3-bromo-N-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-5-fluoro-benzamide 
• 179898-34-1 3-bromo-5-fluorobenzonitrile 
• 933585-20-7 3-bromo-5-fluorophenylamide 
• 1312923-99-1 3-(2-(5-methylpyridin-2-yl)ethynyl)-5-fluorobenzonitrile 

Relevant articles and documents

Discovery and characterization of AZD9272 and AZD6538 - Two novel mGluR5 negative allosteric modulators selected for clinical development

AZD9272 and AZD6538 are two novel mGluR5 negative allosteric modulators selected for further clinical development. An initial high-throughput screening revealed leads with promising profiles, which were further optimized by minor, yet indispensable, structural modifications to bring forth these drug candidates. Advantageously, both compounds may be synthesized in as little as one step. Both are highly potent and selective for the human as well as the rat mGluR5 where they interact at the same binding site than MPEP. They are orally available, allow for long interval administration due to a high metabolic stability and long half-lives in rats and permeate the blood brain barrier to a high extent. AZD9272 has progressed into phase I clinical studies.

Fluorine-flanked congested sites: Minimal, though perceptible buttressing effects on the proton mobility of arenes

(2,6-Difluorophenyl)trimethylsilane, -triethylsilane and -triisopropylsilane undergo sec-butyllithium-mediated metalation at the 3- and 4-position (ortho and meta relative to the halogen) in ratios of 99.6:0.4, 98:2 and 95:5, respectively. The steric pressure transmitted by the fluorine atoms can be increased if the trialkylsilyl group is locked up on the other side by a relatively voluminous substituent. Whereas (2,6-difluorophenyl)triethylsilane is attacked by lithium 2,2,6,6-tetramethylpiperidide under deprotonation of the 4- and 5-position in a ratio of 99.4:0.6, the proportion of "ortho"/ "meta" metalation changes to 84:16 when (2-bromo-6-fluorophenyl) triethylsilane acts as the substrate. Wiley-VCH Verlag GmbH & Co. KGaA, 2005.